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β-thalassemia is characterized by reduced or absence of β-globin production, resulting in anemia. Current therapies include blood
transfusion combined with iron chelation. BM transplantation, although curative, is restricted by the matched donor limitation.
Genetherapy,ontheotherhand,ispromising,anditssuccessliesprimarilyondesigningeﬃcientglobinvectorsthatcaneﬀectively
and stably transduce HSCs. The major breakthrough in β-thalassemia gene therapy occurred a decade ago with the development
of globin LVs. Since then, researchers focused on designing eﬃcient and safe vectors, which can successfully deliver the therapeutic
transgene, demonstrating no insertional mutagenesis. Furthermore, as human HSCs have intrinsic barriers to HIV-1 infection,
attention is drawn towards their ex vivo manipulation, aiming to achieve higher yield of genetically modiﬁed HSCs. This paper
presents the current status of gene therapy for β-thalassemia, its success and limitations, and the novel promising strategies
available involving the therapeutic role of HSCs.
1.Introduction
The β-thalassemias represent inherited, monogenic anemias,
arising from autosomal recessive mutations, aﬀecting the
synthesis of the β-chain of hemoglobin [1]. They are
characterized by reduction or absence of β-chain synthesis,
resulting in excess of α-chain molecules, which precipitate
in red blood precursors, leading to impaired erythrocyte
maturation, mechanical damage, and ultimately to apoptosis
[2]. Thalassemias are caused by more than 200 mutations
aﬀecting the human β-globin gene and are most prevalent
in the Mediterranean region, the Middle East, India, and
South East Asia, representing a serious health problem.
Lately, due to population migration, β-thalassemia presents
a clinical problem also in UK, US, and Australia. Globally, it
is estimated that there are 80 million carriers [3].
β-thalassemic phenotype is very heterogeneous and
directly linked to the genotype. In heterozygotic state, the
outcomeisconsistentwithclinicallynormalindividuals,who
are largely unaware of their genetic condition. Inheritance
of two copies of β-thalassemia genes causes thalassemia
major and usually results in life-threatening anemia and
transfusion-dependencetreatmentforsurvival.Intermediate
clinical forms of the disease exist as thalassemia intermedia,
which is characterised by moderately severe anemia with
occasional need for blood transfusion.
Current therapies for β-thalassemia include blood trans-
fusions together with life-long iron chelation and hydrox-
yurea treatment for fetal hemoglobin (HbF) induction.
Although these strategies have improved patients’ mortality
and have signiﬁcantly delayed the onset of iron-related organ
failure, treatment noncompliance is common, leading to car-
diac,hepatic,orendocrinefailure[4].Allogeneichematopoi-
etic stem cell (HSC) transplantation of human leukocyte
antigen- (HLA-) matched sibling donors can be curative,
reaching cure rates up to 90% in patients younger than 17
years of age [5]. However, it is associated with a number of
drawbacks, such as the limited matched related donors and
the need for long-term immunosuppression to prevent, treat
or delay graft-versus-host disease (GVHD), often associated2 Stem Cells International
with allogeneic HSC transplantation. Therefore, an alterna-
tivemolecularstrategybasedongenetherapyisundoubtedly
a radical approach that overcomes all the above limitations.
2. Designing Effective Vectors for
β-Thalassemia Gene Therapy
Most research eﬀorts towards gene therapy for β-thalassemia
have focused on employing retroviral vectors as a means of
genedelivery, since theseare capableto integrate into the tar-
getcellgenome,resultinginstableandlong-termexpression.
However, the integration has to be targeted and should occur
inaspeciﬁcmannerinordertoavoidpoorgeneexpressionor
even silencing. Therefore, for gene therapy for β-thalassemia
to become an eﬀectiveandrealistictherapeuticapproach,the
following very important criteria need to be met:
(I) the therapeutic vector should exhibit stability, high
titer and erythroid-lineage speciﬁcity, via the utiliza-
tion of respective regulatory elements,
(II) the transgene must be expressed in therapeutic and
sustained levels,
(III) the therapy itself should be safe and eﬃcient in terms
of viral transduction.
Early attempts back in the 1980s and 1990s utilized gam-
maretroviral vectors to achieve stable and high-level trans-
gene expression, however, with no success. More speciﬁcally,
Williams et al. [6] managed to introduce a marker gene
into murine HSCs, using a vector, derived from murine
leukemia virus (MLV) after replacing gag, pol, and env gene
with the transgene of interest, while later on, investigators
utilized these vectors to drive expression of β-globin genes
into murine HSCs [7–9]. The outcome, however, was
unsatisfactory, as poor gene-transfer eﬃciency was obtained,
with levels of β-globin reaching 0%–2% of the endogenous
RNA levels. In an attempt to increase β-globin expression,
Novak et al. [10] incorporated into MLV the newly identiﬁed
powerful DNA-enhancer elements from the β-globin locus
control region (LCR), which is found to be essential for
high-levelexpressionofglobingenes[11,12].Unfortunately,
poor vector production and genetic instability of the viral
vector genome were observed under these experimental
conditions, primarily due to the large size of the fragments
incorporated into the vector. Extensive mutagenesis studies
of the transduced β-globin gene by Leboulch et al. [13]
identiﬁed a 372bp intronic segment and multiple reverse
polyadenylation and splicing events, which were responsible
for low viral titers and instability of proviral transmission,
upon infection. Around the same time, Sadelain et al.
[14] managed to generate a high-titer retroviral vector that
expressed high levels of β-globin in an erythroid-speciﬁc
manner, by combining the human β-globin gene and the
LCR core hypersensitive sites (HS) 2, 3, and 4; however, the
group failed to reduce positional variability of expression.
Taken together, the above ﬁndings indicated that vector
instability might be caused by splicing of the retroviral
RNA genome, a consequence of cryptic splice sites within
the genomic sequences [13, 14]. A way to circumvent
the above was to turn towards lentiviral vectors (LVs), as
the latter, in addition to the common Gag, Pol, and Env
proteins, also encode Tat and Rev. A major function of
Rev is to mediate nucleoplasmic export of unspliced viral
RNA, allowing thus the production of full-length viral RNA
genomes [15]. Therefore, Rev expression in a LV packaging
line could prevent splicing of a β-globin vector, containing
large genomic fragments, leading thus to vector stability.
A major breakthrough in the gene therapy ﬁeld for
hemoglobinopathies took place when May et al. [16]a n d
Pawliuk et al. [17] constructed an HIV-based vector with
the β-globin gene along with its LCR and managed to
achieve high titers, which in turn allowed high expression
of the therapeutic gene and thus disease amelioration.
Following this approach, several groups working also on
hemoglobinopathies employed β-globin LVs in their studies,
obtaining signiﬁcant results, leading to correction of β-
thalassemia [18] in murine models, as will be discussed
below. Although the above vectors were able to ameliorate
the phenotype of β-thalassemia, the observation that com-
pound thalassemic patients with the syndrome of hereditary
persistence of fetal hemoglobin (HPFH) typically have less
anemia,milderclinicalsymptoms,andareoftentransfusion-
independent, drew the attention towards constructing γ-
globin vectors [19].
Persons and colleagues designed such vectors, containing
also the extended β-globin LCR, and managed to show
signiﬁcant correction of the thalassemic phenotype [20].
However, globin expression by these vectors was inconsistent
because of chromosomal position eﬀects albeit the curative
eﬀect they were capable to demonstrate, and eventually led
to the use of chromatin insulators [21].
Insulators represent DNA elements capable to shield the
therapeutic gene from the negative and/or positive eﬀects of
the surrounding DNA, leading thus to higher and more con-
sistent expression and reducing also vector genotoxicity by
preventing the viral regulatory elements to interfere with the
expression of ﬂanking genes. A recent study has shown that
improved and more consistent globin gene expression can be
obtained when a 1.2kb DNA element from the chicken β-
globinlocus(cHS4)isincorporatedintotheglobinLVdesign
[21]. Unfortunately, this vector design can lead to a signiﬁ-
cant reduction in vector production and titer and seriously
compromise practical use; the mechanism underlying this
decrease has been recently elucidated for the ﬁrst time [21].
However, when Hanawa et al. [22], included only the 0.25kb
core element of cHS4, it was shown that the speciﬁc element
could rescue vector titer by alleviating a postentry block
to reverse transcription associated with the 1.2kb element.
Also, in an orientation-dependent manner, the 0.25kb
core element signiﬁcantly increased transgene expression
from an internal promoter due to improved transcriptional
termination.Thiselementalsodemonstratedbarrieractivity,
reducing variability of expression due to position eﬀects.
Similarly, Lisowski and Sadelain [23] showed that the incor-
poration of HS1 element enhances the therapeutic eﬃcacy of
the globin gene transfer in murine β-thalassemia, compared
to HS2-HS3-HS4 alone and, therefore, can lead to even
higher globin expression with lower vector copy numbers.Stem Cells International 3
Also, for safety reasons and in order to avoid insertional
mutagenesis complications as in the SCID clinical trial [24],
all research groups have employed a self inactivating (SIN)
conﬁguration in their vectors, by deleting large fragments
of the U3 region within the vectors’ long terminal repeat
(LTR).
3.Hematopoietic StemCells(HSCs)and
LentiviralGlobinVectors
A schematic representation of the HSC-based gene therapy
for β-thalassemia is shown in Figure 1. HSCs represent a
minor population of the adult bone marrow, accounting for
1 in 2,500 to 1 in 10,000 cells in the adult mouse [25, 26].
These cells remain relatively quiescent most of their lives,
with murine HSCs entering cell cycle every 1-2 months [27],
while in primates and humans, the turnover rate is even
slower reaching 1-2 years [28]. Due to the above features,
gene therapy for hemoglobinopathies focused on employing
such vectors for gene delivery, as they can eﬃciently infect
nondividing cells, and thus manage to deliver the transgene
of interest [29]. However, it should be noted that although
L V sm a yb ea b l et oi n f e c tH S C si nG o phase, it has been
clearly shown that HSCs exiting Go and entering G1b phase
aremorereadilytransduced[30],possiblyduetothefactthat
reverse transcription occurs at this stage [31].
3.1. Correction of Murine β-Thalassemia. As mentioned
above, the major breakthrough in the correction of β-
thalassemia came from the group of Sadelain in New York,
where they managed to correct thalassemia intermedia in
a murine model [16] and later in rescuing lethality in a
thalassemia major model [32], using TNS9 β-globin vector.
I np a r a l l e l ,P a w l i u ke ta l .[ 17] demonstrated that lentiviral-
mediated stem cell transfer of an antisickling variant of the
human β-globin chain resulted in hematologic correction
and diminished end-organ damage in murine sickle cell
disease (SCD). Similarly, Imren et al. [33] using a β-
globin vector showed that β-globin expression reached
approximately 32% of the total hemoglobin, while in the
caseof the GLOBEvector,the Ferrari groupshowed β-globin
expression ranging from 14 to 37% [18].
Correction of β-thalassemia was also achieved using γ-
globin vectors, as mentioned previously, with the Persons
group being the ﬁrst to construct and test such vector.
In their ﬁrst attempt, using a noninsulated vector, they
managed to correct thalassemia intermedia in the murine
model. However, the phenotypic correction varied due to
chromosomal positioning eﬀects and vector copy number
[20]. In an attempt to address these issues, Arumugam et al.
[21] incorporated the cHS4 insulator in the D432β-4γ vector
and succeeded in increasing the transgene’s expression, in
the expense of viral titers though. Similarly, Hanawa et al.
[34] demonstrated that animals receiving transplants of β-
thalassemic stem cells transduced with a new LV, containing
3.2kb of LCR sequences, expressed high levels of fetal
hemoglobin, ranging from 17% to 33%, with an average
vector copy number of 1.3. The above strategy led to a mean
increaseinhemoglobinconcentration(26g/L)andenhanced
amelioration of other hematologic parameters [34].
Lastly, Zhao et al. from the Persons group went further
and incorporated a drug-resistance gene, methylguanine
methyltransferase (MGMT), in the γ-globin vector [35],
demonstrating amelioration of murine β-thalassemia and
enrichment of the corrected HSC compartment, employing
in vitro and in vivo selection, following drug treatment.
However, despite the successful drug-induced enrichment
of the HSC pool in the above study, ﬁndings from other
investigators tend to suggest that MGMT selection approach
may not always result in the desired outcome and quite often
is accompanied by drug-related toxicity. More speciﬁcally,
Larochelle et al. [36] failed to induce selection of long-
term repopulating HSCs in rhesus macaques and showed
thatthealkylatingagentbis-chloroethylnitrosourea(BCNU)
can result in signiﬁcant nonhematopoietic toxicity, such as
pulmonary congestion/edema and necrohemorrhagic colitis.
In addition, recent work by Giordano et al. [37] using a
murine serial transplant model demonstrated that MGMT
selection approach can also lead to insertional mutagenesis
and clonal dominance. Taken together, the above data
indicate that although MGMT selection approach can be
an eﬀective strategy for enrichment of the corrected HSC
compartment, its drug-related toxicity and insertional muta-
genesispotentialrepresentconsiderableriskfactorsforusein
human clinical trials.
3.2. In Vitro Studies with Human HSCs. Both β-globin and
γ-globin vectors have been used in correcting human
erythropoiesis in erythroid cultures and immunodeﬁcient
mice. In a detailed study, Puthenveetil et al. [38]t e s t e da
lentiviral vector carrying the human β-globin expression
cassette, ﬂanked by a chromatin insulator in transfusion-
dependent human thalassemia major, and demonstrated
that normal amounts of human β-globin were expressed in
erythroid cells produced in vitro; erythropoiesis was restored
and apoptosis signiﬁcantly reduced. These gene-corrected
humanβ-thalassemiaprogenitorcellswerethentransplanted
into immunodeﬁcient mice, where they were capable of
establishing normal erythropoiesis. In addition, Roselli et al.
[39], using the GLOBE vector, reported successful correction
of thalassemia major in human cells by achieving high
transduction frequency, restoration of hemoglobin A syn-
thesis, rescue from apoptosis, and correction of ineﬀective
erythropoiesis.
Similarly, Persons and colleagues, using diﬀerent γ-
globin vectors and an in vitro model of human erythro-
poiesis, showed recently that both lentiviral-mediated γ-
globin gene addition and genetic reactivation of endogenous
γ-globin genes have the potential to provide therapeutic HbF
levels to patients with β-globin deﬁciency [40, 41]. Finally,
the group of Anagnou, to address the issues of low titer,
variable expression, and gene silencing, aﬀecting the gene
therapy vectors for hemoglobinopathies, has successfully
used the HPFH-2 enhancer in a series of oncoretroviral
vectors [42]. Based on these data, the same group [43]
generated a novel insulated SIN LV designated as GGHI,4 Stem Cells International
containing the Aγ-globin gene with the −117 HPFH point
mutation and the HPFH-2 enhancer. This vector managed
to produce eﬃcient amounts of HbF resulting in phenotypic
correction in erythroid cultures of CD34+ HSCs isolated
from peripheral blood (PB) or bone marrow (BM) [43].
In this speciﬁc vector design, the incorporation of the full-
length 1.2kb cHS4 in the U3 region and the SIN conﬁgu-
ration had no apparent eﬀect on viral titer, since it reached
2 × 108 TU/mL. Eﬀorts have also been made in the ability
of γ-globin vectors pseudotyped with diﬀerent envelope
glycoproteins to transduce human HSCs [44] that resulted
in the notion that the vesicular stomatitis virus glycoprotein
(VSVG) is more eﬀective in transducing engrafting cells than
other gammaretroviral glycoproteins, supporting thus its use
in clinical-grade vectors [44].
3.3. The First Clinical Trial. The ﬁrst human clinical trial
using a β-globin LV commenced in France on June 7, 2007,
where Leboulch and colleagues selected two β-thalassemia
patients who underwent transplantation of LV-transduced
HSCs [45, 46]. The ﬁrst one, a 28-year-old patient expe-
rienced a period of prolonged aplasia likely due to the
technical handling of the cells, without relation to the gene
therapy vector, and despite the absence of any adverse eﬀects,
required the administration of untransduced cells kept as a
backup, in order to avoid putative infections. As a result, the
lentiviral-modiﬁed cells did not reach a signiﬁcant level in
PB, neither did the therapeutic hemoglobin, leading to no
conclusions regarding the speciﬁc patient.
The second patient in the study was a 18-year-old male
suﬀering from HbE/β◦ thalassemia, a form of the disorder in
which hemoglobin production is severely compromised. He
was transfusion-dependent since the age of three, requiring
160mL of packed erythrocytes/kg/year. He received 4 ×
106 CD34+ cells/kg [46]. The levels of genetically modiﬁed
cells increased from 2% in the ﬁrst few months to 11% at
33 months posttransplant. The above rise was also observed
in the levels of normal β-globin protein, with 10%-20% of
HSCs being genetically modiﬁed, leading thus to improved
production and quality of red blood cells. Remarkably, a year
after the treatment, the patient no longer required blood
transfusions.HewaslasttransfusedonJune6,2008,andfour
years after transplantation, despite being slightly anemic and
undergoing repeated phlebotomies for the decrease of iron
overload, the patient does not require blood transfusions,
which means that this single case can be viewed as a clinical
success.
However, despite the successful outcome of the second
patient,Cavazzana-Calvoetal.reportedthatonehematopoi-
etic clone, harboring a vector insertion into the HMGA2
gene showed clonal dominance [46]. At 20 months post
transplantation, the speciﬁc clone accounted for 50% of
the genetically modiﬁed HSCs; its contribution, however, to
the circulating red blood cells’ pool remains at around 3%.
The potential clinical relevance of the alteration of HMGA2
expression by the vector integration is highlighted by the
fact that this gene may function as a potential oncogene in
various types of cancer. However, it remains unclear whether
the vector insertion into this gene has actually resulted in the
relatively high contribution of this clone to hematopoiesis,
since it is conceivable that the above observation may simply
reﬂecttheconsequencesofengraftmentfromasmallnumber
of transduced HSCs.
In summary, the above patient represents the proof of
principle that gene therapy can be a successful therapeutic
approach. This successful clinical trial demonstrated that
large amounts of a therapeutic protein can be produced in
vivo in a lineage-speciﬁc manner and validated somatic gene
transfer using a lentiviral SIN vector for transducing long-
term repopulating HSCs. It also demonstrated that somatic
gene transfer ex vivo can provide transfusion independence
for patients with severe forms of thalassemia.
4. EnhancingLentiviralGene
Transfer Efﬁciency in Human and
Nonhuman PrimateHSCs
As discussed above, studies from many laboratories have
shown that murine HSCs can be genetically modiﬁed using
both β-globin and γ-globin LVs and engraft, resulting in
amelioration of β-thalassemia. However, this is not the case
for both human and nonhuman primate HSCs. These types
are more resistant to lentiviral gene transfer and so far,
no more than 10%–15% of genetically modiﬁed peripheral
blood cells have been achieved. Recent work on rhesus
macaques [47] using GFP LV demonstrated an average of
7% LV-bearing peripheral blood cells, a ﬁnding that comes
into agreement with previous studies on pigtail macaques
[48, 49]. Similarly, the 18-year-old patient in the ﬁrst clinical
trial discussed above showed an average of 15% genetically
modiﬁed HSCs [46], supporting even further the notion that
higher percentages of genetically modiﬁed HSCs in the case
of human and nonhuman primates is not an easy task. The
most eﬀective strategies shown to increase HSC yield are
described below and are also shown in Figure 1.
4.1. HSCs and Cellular Factors. The resistance of primitive
human and nonhuman primate HSCs to infection by HIV-
based vectors has drawn a lot of attention in the past decade.
Recent work by the Naldini group [50] demonstrated that
lentiviral gene transfer is limited by the proteasome through
the regulation of one or more of the cellular postentry steps
of the vector particle. Experiments involving the proteasome
inhibitor MG132 during LV transduction demonstrated a
4-fold increase in gene transfer into human CD34+ cells
[50]. In this study, the transient and reversible inhibition
of proteasome function did not lead to any obvious HSC
defects. However, as proteasome is the major cellular pro-
teolytic machinery, inhibition of its function may lead to
cellular toxicity, through rapid accumulation of proteins
in cells, resulting in impairment of their survival. Thus,
the use of proteasome inhibitors as a means of increasing
lentiviral HSC transduction needs further investigation,
before it is considered safe to use in clinical trials. Lastly,
in a diﬀerent study by Zhang et al. [51], cell-cycle protein
p21, which is found at high levels in HSCs, was identiﬁed
as a unique molecular barrier to HIV infection, through itsStem Cells International 5
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Figure 1: Schematic representation of HSC-based gene therapy for β-thalassemia. BM CD34+ cells are removed from the patient (right
panel), transduced in vitro with the therapeutic globin LV, carrying the preferred envelope glycoproteins, and returned to the patient
intravenously. At this stage, and primarily in the case of human HSCs, ex vivo expansion and proliferation can be induced; alternatively,
selection of genetically modiﬁed HSCs may take place. Both strategies can lead to increased yield of corrected HSCs, which will contribute
to the HSC compartment, when returned to the patient. Alternative strategies for obtaining higher yield of CD34+ cells are continuously
emerging (left panel). These include mobilization of BM CD34+ HSCs with mainly G-CSF and then isolation of these cells from peripheral
blood. Moreover, iPS cell strategy suggests that somatic cells from the patient can be reprogrammed to iPS cells and after genetic
manipulation, involving genetic correction for the mutations by homologous recombination, these cells can give rise to globin-producing
HSCs, following directed hematopoietic diﬀerentiation.
interactions with the viral integrase, leading to inhibition of
chromosomal integration [51].
4.2.HSCCyclingandExpansionExVivo. Apartfromcellular
factors being important for lentiviral gene transfer into
human HSCs, another crucial characteristic that impairs
the eﬃciency of the gene transfer is the low levels of
ex vivo HSC cycling. As mentioned earlier, human HSCs
remain quiescent longer than murine ones, with the former
entering G1 every 30–40 weeks [28], compared to just 4–
8w e e k s[ 27] in the murine case. These ﬁndings, together
with the fact that HSCs are more readily transduced when
they enter cell cycle, point towards the need for in vitro
proliferation and expansion of HSCs destined for lentiviral
gene transfer. Major eﬀorts have focused on research into
novel culture conditions, which can lead to HSC expansion
andproliferation.Promising candidatesforthesefeaturesare
angiopoietin-likeproteins,whichareshowntoinduceexvivo
expansion of human cells that repopulate immunodeﬁcient
mice[52,53].Also,transcriptionfactorssuchasHOXB4[54]
and NUP98-HOX fusion protein [55] have also been shown
to induce HSC expansion. Furthermore, a purine derivative
called stem regenin1 (SR1) was also shown to promote
ex vivo expansion of CD34+ cells, by acting as an aryl
hydrocarbonreceptor(AHR)antagonist,leadingtoa50-fold
increase in CD34+ cells and a 17-fold increase in cells that
retained their ability to engraft immunodeﬁcient mice [56].
SR1 was shown to directly bind AHR and inhibit AHR
signaling, which is implicated in hematopoiesis regulation.
Recent work by Wang et al. [57] showed that inhibition of
mitogen-activated protein kinase (MAPK) p38 could also
result in ex vivo expansion of HSCs. This increase in HSC
expansion is likely attributable to the p38 inhibitor-mediated
inhibition of HSC apoptosis and senescence and to the
upregulation of HOXB4 and CXCR4. Although the above
studyusedmurinelineagenegativecells,thefactthatresulted
in HOXB4 upregulation, already shown to be essential for
human HSC expansion, suggests that it is very likely to be
eﬀe c t i v ei nh u m a nH S C sc a s ea sw e l l .
4.3. Selection of Genetically Modiﬁed HSCs. As mentioned
above, increasing the levels of genetically modiﬁed human
HSCs following lentiviral gene transfer is not an easy task.
Various approaches have been employed in order to achieve
this goal. Zhao et al. [35] incorporated the drug-resistance
gene MGMT, which confers resistance to several potent
hematopoietic toxins such as BCNU, in their γ-globin LV
and managed to show signiﬁcant amelioration of the disease
in the murine model [35]. The globin-expressing HSCs
were selected in vivo by cytotoxic drug administration and
reached high levels, suﬃcient to ameliorate the disease.
Moreover, this system allowed also an in vitro selection of
the transduced cells, prior to transplantation, which led to
enrichment of the γ-globin-expressing cells compartment.6 Stem Cells International
However, despite the successful application of the above
approach in murine models, there are major caveats for
clinical applications, primarily due to the alkylating agents-
related genotoxicity and the insertional mutagenesis poten-
tial, as discussed previously in this paper. Lastly, it is feasible
in a system where cell numbers are not a limiting step, which
usually is not the case for human HSCs.
4.4. Packaging Envelope Glycoproteins. Another promising
strategy for increasing human HSC lentiviral transduction
is by designing vectors that carry ligands on their envelope,
which match the receptors on target cell. In a recent
pioneering work by Verhoeyen et al. [58], it was shown that
HSC gene transfer is signiﬁcantly increased when lentiviral
particles are engineered to display early acting cytokines
on their surface. The rationale behind the above strategy
is that these modiﬁed LVs would selectively and minimally
stimulate HSCs within the CD34+ cell population, leading
to increased transduction and thus gene transfer. Finally,
the use of the alternative envelope protein RD114 [59,
60] represents another good candidate for enhancing viral
transduction and might be used as an alternative to the more
cytotoxic VSVG protein.
5. AlternativeStrategiesfor Obtaining
More HSCs with Less Effort
Apart from manipulating the ex vivo culture conditions and
the HSC state, researchers have demonstrated additional
meansofincreasingtheHSCyield,suchasHSCmobilization
and the generation of induced pluripotent stem (iPS) cells
(Figure 1)a sd e s c r i b e db e l o w .
5.1. HSC Mobilization. The term HSC mobilization refers
to the forced migration of HSCs from the BM to the
bloodstream.MobilizedPBcanthenbeusedasanalternative
source for CD34+ cells for lentiviral transduction, gene
transfer, and eventual transplantation for the treatment of β-
thalassemia, yielding a 3 to 4-fold enrichment [61]. Lately,
this strategy has drawn the attention of many research
groups, with granulocyte colony-stimulating factor (G-CSF)
being the major inducer of peripheral blood stem cell
(PBSC) mobilization, alone or together with chemotherapy
[61, 62], and has speciﬁcally gained ground in the ﬁeld
of gene therapy for β-thalassemia. Particularly, Li et al.
[63] assessed the administration of G-CSF in mobilizing
stem and progenitor cells in thalassemic major pediatric
patients and compared the kinetics of CD34+ cells and
lymphocyte subsets with those of healthy PBSC donors.
Results showed that CD34+ cells in 20 thalassemic patients
and11healthydonorswereeﬀectivelymobilizedbyG-CSFin
concentrations of 10–16μg/day/kg of weight. No signiﬁcant
diﬀerence was observed in the levels of daily stem cell
counts between the two groups of subjects, demonstrating
that under close monitoring of CD34+ cell levels in PB,
the mobilization by G-CSF and collection of PBSCs in
β-thalassemia patients are feasible [63]. Recently, Yannaki
et al. [64] have mobilized murine HSCs using G-CSF and
showed that thalassemic mice mobilized less eﬃciently than
their control counterparts due to increased splenic trapping
of HSCs and progenitor cells. The reduced mobilization
eﬃciency was restored when splenectomy was performed
in HBBth−3 mice, suggesting that for human gene therapy,
HSC mobilization may require more than one cycle or
alternativeprotocols,soastoyieldsuﬃcientHSCsforgenetic
manipulation and transplantation.
Regarding the French ongoing clinical trial, following
authorization from the regulatory agency may already use
either BM-derived or peripheral blood G-CSF mobilized
CD34+ cells [45].
5.2. Induced Pluripotent Stem (iPS) Cells. i P Sc e l l sa r eg e n e -
rated by reprogramming a diﬀerentiated somatic cell into
a pluripotent embryonic stem cell (ESC) [65]. These iPS
cells, which are identical to human ESCs, have the potential
to give rise to every cell type in the human body. The
genes and surface proteins expressed in these cells are
almost identical to those expressed in ESCs and, therefore,
can be eventually used to correct mutant cells or tissues
by homologous recombination. Thus, somatic cells from
a patient may be isolated and reprogrammed to iPS cells,
employing genes such as Oct3/4, Sox2 with either Klf4 and
c-Myc or Nanog and Lin28, and after genetic manipulation
and diﬀerentiation to the desired cell lineage, they could
be administered back to the patient, maintaining, at least
theoretically, the same properties and characteristics [65].
There are diﬀerent techniques for pluripotency induction,
and these are extensively reviewed by Patel and Yang [65]
and have been presented in detail in a recent special issue of
this journal [66]. Brieﬂy, they include somatic cell transfer,
cell fusion, reprogramming through cell extracts, and direct
reprogramming using mainly viral vectors, proteins, RNAs,
microRNAs (miRNAs), and small molecules.
iPS cell technology seems quite promising in the context
of human gene therapy for β-thalassemia, as it provides
an alternative and patient-friendly strategy for obtaining
higher number of HSCs for genetic manipulation and
transplantation. The ﬁrst reported gene correction in the
context of hemoglobinopathies, using iPS cells, was per-
formed in an SCD mouse model. Hanna et al. [67]h a rv e s t e d
cells from the skin of the SCD mouse and reprogrammed
them to ESCs, by retrovirally delivering Oct4, Sox2, Lif4,
and c-Myc genes. After removing c-Myc to decrease or
eliminate putative tumorigenesis in treated mice, ESCs were
cultured to produce BM stem cell precusors, and following
replacement of the defected gene with a normal one, via
homologous recombination, they were transplanted back to
SCD mice. The outcome was disease amelioration in these
mice, with blood and kidney function returning to normal
levels. Following the murine study, Ye et al. [68] were the
ﬁrst to show that this issue is also feasible in humans, as they
managed to reprogram skin ﬁbroblasts from a thalassemic
patient with β◦ thalassemia into iPS cells, and demonstrated
that the latter, following gene targeting, could diﬀerentiate
into hemoglobin-producing HSCs.
Such gene targeting, however, needs to be highly con-
trolled, as randomly integrated transgenes may result inStem Cells International 7
oncogenicity, and therefore, a general need for a strategy
to introduce transgenes into “safe” regions in iPS cells is
imperative. A good approach to overcome this obstacle
came recently from the Sadelain group [69], where they
managed to induce β-globin transgene expression in iPS
cell clones, where the LV had integrated in “safe harbors”
throughout the genome. iPS cells in this study originated
from skin ﬁbroblast or BM mesenchymal cells from patients
suﬀering from β-thalassemia major. In order to identify safe
harborsfortransgeneintegrationinthehumangenome,they
employed bioinformatics and functional analysis. Retrieval
of safe harbor sites (i.e., safe integration sites) met the
following ﬁve criteria: (i) distance of at least 50kb from the
5  end of any gene, (ii) distance of at least 300kb from any
cancer-related gene, (iii) distance of at least 300kb from any
miRNA coding gene, (iv) location outside a transcription
unit,and(v)locationoutsideultraconservedregions(UCRs)
of the human genome. Measurement of β-globin expression
in these progenitors reached high levels, suggesting that the
above strategy, once improved, can be very eﬃcient for β-
thalassemia.
6. Summary
The eﬃcient gene delivery of therapeutic transgenes using
LVs has become a milestone in the ﬁeld of gene therapy
for hemoglobinopathies. Improved LV design enabled suc-
cessful introduction of transgenes into both murine and
human HSCs, leading to amelioration of β-thalassemia
in murine models, and restored erythropoiesis in vitro.
Extensive studies in the ﬁeld led also to the success of
the ﬁrst clinical trial in France, in June 2007, where a
18-year-old HbE/β◦ thalassemic patient was treated with
a β-globin vector and a year after BM transplantation
managed to become transfusion-independent. As of today,
he remains transfusion-independent, for over three years,
in spite of repeated phlebotomies aimed to decrease iron
overload. Despite the eﬃcacy of LVs to introduce therapeutic
transgenes into HSCs, there is also the risk for insertional
mutagenesis, and therefore, an extensive work is currently
focused on generating safe vectors for gene therapy. The
above is usually achieved by incorporating elements, which
make the vector tissue-speciﬁc and also shield the transgene
from neighbouring eﬀects, upon integration. Regardless
the need for constantly improving vector design, a lot of
attention has been drawn also towards strategies that result
in higher numbers of genetically modiﬁed HSCs, which will
in turn contribute to the HSC pool in the patient. The latter,
together with extensive research towards alternative HSC
sources, such as iPS cells, will undoubtedly set the ground
for more successful clinical trials.
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